Treatments administered to patients with primary IgA nephropathy (IgAN) and those with Henoch–Schönlein nephritis are largely based on opinion or weak evidence, and the recent KDIGO Clinical Practice Guidelines for Glomerulonephritis assigned low levels of evidence for the majority of recommendations and suggestions related to these two diseases. In this Review, Floege and Feehally describe an algorithm for structuring the treatment of IgAN depending on the clinical scenario, and discuss ongoing studies to investigate treatments.
- Jürgen Floege
- John Feehally